An Expanded Access Protocol for ZMapp (Anti-Ebola monoclonal antibody)

Trial Profile

An Expanded Access Protocol for ZMapp (Anti-Ebola monoclonal antibody)

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 27 Oct 2016

At a glance

  • Drugs Porgaviximab (Primary)
  • Indications Ebola virus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Oct 2016 New trial record
    • 12 Oct 2016 According to a Mapp Biopharmaceutical media release, the U.S. Food and Drug Administration (FDA) has approved an Expanded Access Protocol (EAP) for ZMapp. The company will also make appropriate regulatory submissions in the three West African countries that participated in PREVAIL II, and will make ZMapp available to Ebola patients wishing to have access to this experimental treatment in participating countries.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top